Published on March 13, 2013 at 6:01 AM
Ideally, he says, if MSCs work, a patient with a glioblastoma would have some adipose tissue (fat) removed — from any number of locations in the body — a short time before surgery. The MSCs in the fat would be drawn out and manipulated in the lab to carry drugs or other treatments. Then, after surgeons removed the brain tumor, they could deposit these treatment-armed cells into the brain in the hopes that they would seek out and destroy the cancer cells.
Currently, standard treatments for glioblastoma are chemotherapy, radiation and surgery, but even a combination of all three rarely leads to more than 18 months of survival after diagnosis. Glioblastoma tumor cells are particularly nimble, migrating across the entire brain and establishing new tumors. This migratory capability is thought to be a key reason for the low cure rate of this tumor type.
"Essentially these MSCs are like a 'smart' device that can track cancer cells," Quinones-Hinojosa says.
Quinones-Hinojosa says it's unclear why MSCs are attracted to glioblastoma cells, but they appear to have a natural affinity for sites of damage in the body, such as a wound. MSCs, whether derived from bone marrow or fat, have been studied in animal models to treat trauma, Parkinson's disease, ALS and other diseases.
Source: Johns Hopkins University
7eab29e9-83aa-485b-a98b-2647b0108688|0|.0
Posted in: Medical Procedure News | Medical Science News | Medical Condition News
Tags: Bone, Bone Marrow, Brain, Brain Cancer, Brain Tumor, Cancer, Cell, Chemotherapy, Glioblastoma, Medi-Cal, Neuroscience, Neurosurgery, Oncology, Parkinson's Disease, Stem Cell, Stroke, Trauma